理性设计一种新型类型的人类ClpP激动剂通过环开放策略与增强的抗白血病活动
Xinrong Xiang1, Zhengyi Dai1, Baozhu Luo1
1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Journal of medicinal chemistry
|April 15, 2024
概括
一种名为7k的新化合物有效地激活Homo sapiens Casein lysing protease P (HsClpP),并在临床前模型中显示出强大的抗白血病活性,为急性髓性白血病 (AML) 提供了一个有前途的新疗法.
科学领域:
- 生物化学 生物化学
- 药用化学 医学化学
- 在瘤学瘤学.
背景情况:
- 激活Homo sapiens病因溶解蛋白酶P (HsClpP) 是急性髓性白血病 (AML) 的潜在治疗策略.
- 现有的激动剂,如伊米普里ONC201,在AML治疗中表现出有限的疗效.
研究的目的:
- 设计和合成一种具有增强活性的新型HsClpP激动剂类.
- 评估这些新型化合物对AML的治疗潜力.
主要方法:
- 采用了一种环开放策略,该策略基于先前识别的化合物.
- 新型脚手架激动剂的合成.
- 检测HsClpP的蛋白质分解活性和体外抗瘤活性.
- 使用Mv4-11异种移植模型进行体内疗效研究.
- 药物动力学概况.药物动力学概况.
主要成果:
- 化合物7k显著增强了HsClpP的蛋白质活性 (EC50 = 0.79 ± 0.03μM).
- 化合物7k在体外表现出强大的抗瘤活性 (IC50 = 0.038 ± 0.003 μM).
- 在Mv4-11异种移植模型中,内注射7k抑制了88%的瘤生长.
- 化合物7k在体内表现出有利的药理动力学特性.
结论:
- 化合物7k是一种有前途的新型HsClpP激动剂.
- 化合物7k显示出作为AML治疗的抗白血病药物候选药物的显著潜力.
- 需要对7k化合物用于AML治疗进行进一步的研究.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
05:17Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
1.5K
相关概念视频
01:28Structure-Activity Relationships and Drug Design
710
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
710
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.0K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.0K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K